AUDIT ON THE MANAGEMENT OF ECTOPIC PREGNANCY AND PUL WITH METHOTREXATE

Karkhanis P, Pradhan P
Princess of Wales Maternity Unit, Birmingham Heartlands Hospital, Bordesley Green (E).
Birmingham B9 5SS, United Kingdom

Abstract
Methotrexate has been used successfully for the non-surgical management of ectopic pregnancies and pregnancies of unknown location (PUL). We present the results of our Trust-wide annual audit on the use of Methotrexate. Out of the 42 patients that underwent medical management, treatment success was met in 84%. The performance of our service i.e. selection criteria, treatment success with one dose, rate of rupture requiring surgery and side-effects is in-keeping with published evidence and compliant with the RCOG and Trust standards.

Methods
• Trust-wide
• Retrospective
• Case-note analysis
• Duration – 1 year (1st January 2013 to 31st December 2013)
Criteria for Methotrexate
1. Bhcg <3000IU/L
2. Adnexal mass <3.5 cm on USS
3. No fetal heart activity in the ectopic
4. Absence of large amount of free fluid on USS
5. Asymptomatic

Results
• Total number of cases = 42
• Mean Age = 29.8 years (18-41)
• Index pregnancy
  • PUL = 23 (55%)
  • Tubal ectopic = 17 (41%)
  • Cornual = 1
  • Caesarean Scar ectopic = 1
• Written consent and Patient Information Leaflets given to all

Conclusion
Overall, our service is compliant with our guidelines and our performance is in keeping with published evidence. The audit has reminded us that the risk of rupture of the ectopic pregnancy persists at any level of Bhcg and to be vigilant of this. We use this information regularly to counsel our patients about the service.